The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s ...

Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...

On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

A year after kicking off a star-studded campaign to highlight the stories of real patients with atopic dermatitis, Incyte has ...

In less than a month, Americans will head to the polls—or vote by mail—and elect the next president of the U.S. | While a ...

In this interview, recorded live at Digital Pharma East, Kamya Elawadhi – Chief Client Officer at Doceree – discusses the ...

Earlier this year, Evonik unveiled a restructuring project that will result in up to 2,000 layoffs. | After Evonik in March ...

By enhancing patients’ understanding, skills, and confidence, the company is revolutionizing the way healthcare content is ...

By Lalit Saxena, Senior Director of MSAT, and Sungkeum Seo, Director of MSAT Labs Upstream Processing at Samsung ...